Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as pradefovir mesylate
pradefovir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pradefovir mesylate | DRUG | - |
| adefovir dipivoxyl | DRUG | - |
Inclusion Criteria: * Compensated chronic HBV Infection * No prior treatment with adefovir dipivoxil * No interferon or lamivudine treatment for three months prior to enrollment * HBeAg positive or negative * HBV DNA viral load greater than 500,000 copies per mL * ALT between 1.2 and 10 times ULN ...
Pradefovir is an investigational small molecule being studied for the treatment of chronic hepatitis B, a long-term viral infection of the liver. It is in Phase 2 clinical development and is not an approved therapy. It has been evaluated in a dose-ranging study in patients with compensated hepatitis B.
Pradefovir is being developed by Bausch Health Companies Inc., which trades on the New York Stock Exchange under the ticker BHC. The company is the sponsor associated with the clinical program for this hepatitis B candidate.
Pradefovir is in Phase 2 clinical development for chronic hepatitis B. It is an investigational agent and has not been approved by the FDA. One Phase 2 trial has been completed, and no trials are currently listed as active.
Pradefovir has been studied in NCT00230503, a Phase 2 dose-ranging trial titled "Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B." The trial enrolled 220 patients aged 18 years and older, was randomized, and has been completed.
Yes, pradefovir mesylate is another name for pradefovir. The mesylate refers to the salt form of the same active small molecule, so searches for either name refer to the same investigational hepatitis B candidate developed by Bausch Health Companies Inc.
The completed Phase 2 trial, NCT00230503, was a randomized, dose-ranging study in patients with compensated chronic hepatitis B. It enrolled 220 participants aged 18 years and older of any sex, excluded healthy volunteers, and did not use a blinded or controlled design.